Dr Ann LaCasce: T-Cell Engagers Have Improved DLBCL Outcomes, but Questions on Optimal Use Remain

Ann LaCasce, MD, MMSc, director of the Dana-Farber/Mass General Brigham fellowship in hematology/oncology and chair of the Lymphoma Research Foundation’s Scientific Advisory Board, discusses T-cell engager therapies in the diffuse large B-cell lymphoma (DLBCL) landscape.

Related Keywords

Ann Lacasce ,Research Foundation Scientific ,Witht Cell ,Mass General Brigham ,Research Foundation ,Dlbcl ,Diffuse Largeb Cell Lymphoma ,T Cell Engager Therapy ,Cart Cells ,Bispecific Antibodies ,